The MDMX oncoprotein is an important regulator of tumor suppressor p53 activity during embryonic development. Despite sequence homology to the ubiquitin E3 ligase MDM2, MDMX depletion activates p53 without significant increase in p53 level, implicating a degradation-independent mechanism. We present evidence that MDMX inhibits the sequence-specific DNA binding activity of p53. This function requires the cooperation between MDMX and CK1α, and phosphorylation of S289 on MDMX. Depletion of MDMX or CK1α increases p53 DNA binding without stabilization of p53. A proteolytic fragment release assay revealed that in the MDMX-p53 complex, the MDMX acidic domain and RING domain interact stably with the p53 DNA binding domain. These interactions are referred to as secondary interactions because they only occur after the canonicalspecific binding between the MDMX and p53 N termini, but exhibit significant binding stability in the mature complex. CK1α cooperates with MDMX to inhibit p53 DNA binding by further stabilizing the MDMX acidic domain and p53 core domain interaction. These results suggest that secondary intermolecular interaction is important in p53 regulation by MDMX, which may represent a common phenomenon in complexes containing multidomain proteins.
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p53 | MDMX | CK1α | DNA binding | secondary interaction T he p53 tumor suppressor is a transcription factor that plays critical roles in promoting DNA repair, cell cycle arrest, or apoptosis in response to various types of damage and stress (1) . p53 binds to specific DNA sequences as a tetramer. The core domain involved in DNA binding has poor thermostability and can undergo rapid spontaneous denaturation at physiological temperatures (2) . Single amino acid mutations in the p53 DNA binding domain occur in more than 50% of human tumors, resulting in p53 misfolding and accumulation to high levels (3) (4) (5) . The p53 mutants found in tumors are generally deficient for DNA binding and fail to regulate expression of its target genes.
p53 is present at low levels in unstressed tissues because of rapid turnover. This regulation is achieved mainly through MDM2 binding to p53 and acting as an ubiquitin E3 ligase to promote its proteasomal degradation (6, 7) . MDMX is a p53 binding protein with strong sequence homology to MDM2 (8) . Similar to MDM2, MDMX can bind to p53 N-terminal transactivation domain and inhibit p53 transactivation of target genes (9) . However, MDMX lacks robust ubiquitin ligase activity and is unable to target p53 for proteasomal degradation. The prevailing view is that MDMX mainly functions by regulating p53 transcriptional activity, whereas MDM2 regulates p53 degradation (10) . MDMX forms a heterodimer with MDM2 through the C-terminal RING domains. An important role of MDMX-MDM2 interaction is the regulation of MDMX stability. MDMX level is controlled by MDM2-mediated ubiquitination in a stressdependent fashion (11, 12) . Significant degradation of MDMX occurs after DNA damage through phosphorylation on several C-terminal sites, with S367 phosphorylation by Chk2 being most critical (13) . MDMX knockdown in cell culture generally failed to cause significant change in p53 level. Furthermore, MDMX knockout in mice leads to p53 activation without significant stabilization (10) .
In addition to promoting p53 ubiquitination through the RING domain, MDM2 inhibits p53 binding to DNA. The MDM2 acidic domain (AD) has a weak interaction with p53 core domain (14) . MDM2 binding induces conformational change in the p53 core domain, which is detectable by using the Pab240 antibody that recognizes misfolded p53 (15) . In contrast, MDMX alone fails to induce the Pab240 epitope on p53 and does not inhibit p53 DNA binding in vitro (15) . However, earlier findings showed that MDMX knockdown caused a significant increase in p53 transcriptional output (16) . These results led us to investigate the possibility that MDMX inhibits p53 DNA binding in vivo in cooperation with other factors.
A major MDMX-associated protein is casein kinase 1 alpha (CK1α) (17) . CK1α interacts with the central region of MDMX, including the acidic domain and zinc finger, promotes phosphorylation of S289, and stimulates MDMX-p53 binding (17) . Recent studies suggest that CK1α disrupts an intramolecular autoinhibitory interaction between the MDMX N-terminal domain and acidic domain, thus enhancing MDMX-p53 binding (18) . DNA damage induces Chk2-mediated phosphorylation of MDMX at S367 that inhibits CK1α binding, which leads to inhibition of MDMX-p53 interaction (18) .
In this report, we show that in the presence of CK1α, MDMX inhibits the DNA binding activity of p53. Using a proteolytic fragment release assay (PFR), we detected robust interaction between the MDMX AD and RING domain with p53 in the MDMX-p53 complex. CK1α promotes the binding of MDMX AD to the p53 core domain, suggesting a mechanism by which Significance MDMX is a critical regulator of p53 and a potential drug target. The mechanisms by which MDMX inhibit p53 are not fully understood. Results in this report suggest that MDMX inhibits p53 DNA-binding function. Using a protein fragment release assay, MDMX and p53 were found to engage in multiple strong secondary interactions following initial binding through the canonical binding domains. These secondary interactions are involved in blocking p53 DNA binding and stabilizing the MDMX-p53 complex. The results suggest that secondary interactions play important roles in regulating the function of multidomain protein complexes.
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This article is a PNAS Direct Submission. CK1α and MDMX cooperate to inhibit p53. The RING domain of MDMX is also important for stabilizing MDMX-p53 interaction and inactivation of p53. Our results reveal the importance of secondary interactions between MDMX and p53 in regulating p53 activity, which may represent a mechanism commonly used in other protein complexes.
Results

MDMX and CK1α
Cooperate To Inhibit p53 DNA Binding in Vitro. To determine how MDMX inhibits p53 activity, we tested whether MDMX and CK1α cooperate to regulate p53 DNA binding by using an affinity pull-down assay (15) . When the MDM2-p53 complex was purified from cotransfected cells and incubated with oligonucleotide-containing p53-binding site, poor binding to DNA was detected (Fig. 1A) . This result is consistent with the ability of MDM2 to inhibit p53 DNA binding (15) . In contrast, MDMXp53 complex only showed moderate loss of DNA-binding activity compared with FLAG-p53. When MDMX and CK1α were coexpressed with p53, the MDMX-p53-CK1α complex showed a further loss of DNA binding (Fig. 1A) , suggesting that MDMX inhibits p53 DNA binding after forming a complex with CK1α.
To further test the role of MDMX-CK1α interaction, several MDMX mutants were analyzed. The MDMX-C306S mutant (does not bind CK1α because of zinc finger mutation) and MDMX-S289A (CK1α phosphorylation site mutant) failed to inhibit p53 DNA binding in the presence of CK1α. MDMX-S367A cooperation with CK1α was more efficient than wild-type MDMX, presumably because it is resistant to Chk2-mediated phosphorylation that blocks CK1α binding ( Fig. 1 B and C) . Therefore, MDMX-CK1α binding and phosphorylation of S289 by CK1α is important for inhibiting p53 DNA binding. Furthermore, deleting the AD (Δ200-304) abrogated the ability of MDMX to inhibit p53 DNA binding, whereas deleting the RING (1-430) had no effect, suggesting that the AD is critical for inhibiting p53 DNA binding (Fig. 1B) . MDMX inhibition of p53 DNA binding was also confirmed by using electrophoretic mobility shift assay (EMSA). The ability of p53 to induce mobility shift of a probe containing p53-binding site was inhibited by the addition of purified MDMX-CK1α complex. The activity of MDMX was abrogated by mutation of CK1α phosphorylation site and mutation of the p53 binding pocket (Fig. S1 ).
Secondary Binding of MDMX Acidic and RING Domains to p53. To determine how MDMX inhibits p53 DNA binding, we tested whether the MDMX AD binds to the p53 core domain. When p53-loaded beads were used to capture MDMX mutants, only the mutants containing intact N-terminal 1-100 region (canonical p53BD) were able to bind p53 (Fig. S2A ). In the second assay, a cleavable MDMXc3 construct was used for the analysis. MDMXc3 contains PreScission cleavage sites and epitope tags inserted into three flexible regions of MDMX (19) . Cleavage by PreScission produces four fragments containing different eiptopes (Fig. S2B ). When MDMXc3 expressed in H1299 cells was cleaved with PreScission and then incubated with p53 beads, significant capture of the MDMX N terminus was detected by p53-1-393 and p53-1-80 (Fig. S2C , Bottom), both containing the canonical-binding site for MDMX. Other MDMX fragments were not captured by p53, indicating that only the MDMX N terminus has strong binding to the p53 N terminus when presented individually to p53.
To test whether there are intermolecular interactions in the MDMX-p53 complex that conventional pull-down assays failed to detect, MDMXc3 was first captured with GST-p53 beads and then subjected to on-bead cleavage by PreScission. We hypothesized that after cleavage of the complex, MDMX fragments that engage in binding to p53 will dissociate slowly compared with fragments that have no affinity for p53. We refer to such experiments as PFR assay ( Fig. 2A) . The PFR analysis revealed that in addition to the canonical N-terminal binding, the MDMX AD and RING fragments also showed significant association with p53 (Fig. 2B) . Furthermore, the RING domain binding to p53 was as stable as the p53BD fragment, with >75% remaining bound to the beads after cleavage of MDMXc3. In contrast, the SQ fragment was completely released in the same time span (Fig.  2B) , providing an internal control. Therefore, the PFR analysis uncovered stable binding of MDMX AD and RING domains to p53 in the full-length complex. The AD-p53 binding was detergent-sensitive, suggesting it is mainly mediated by hydrophobic interactions (Fig. S3A) .
To confirm that the novel interactions also occur in MDMXp53 complex formed in vivo, the p53 antibody Pab421 was used to capture the p53-MDMXc3 complex from H1299 cells. The p53-MDMXc3 complex was digested with PreScission, and the release of MDMX fragments was analyzed. The result also showed strong AD and RING fragment binding to immobilized p53 (Fig. 2C) . Overall, the results suggest that after specific binding mediated by the MDMX and p53 N termini, the MDMX AD and RING also establish robust binding to p53. We refer to these interactions as secondary binding, because they require initial interaction through the N terminus of MDMX ( Fig. 2A) . Once the MDMX-p53 complex was formed, the AD and RING binding to p53 no longer required the p53BD, because adding the MDMX N-terminal pocket binding peptide pDI during PreScission cleavage promoted the release of p53BD fragment, but did not promote AD and RING dissociation (Fig. S3C) .
MDMX Acidic and RING Domains Interact with p53 Core Domain. To map the secondary binding sites for the MDMX AD and RING domains on p53, p53 mutants were used to capture MDMXc3, followed by PFR analysis. The results showed that p53-1-300 and p53-1-393 bound to the p53BD, AD, and RING. P53-1-82 bound to the p53BD but not AD and RING (Fig. 3A) . Therefore, the core domain of p53 (83-300) contains the secondary binding sites for MDMX AD and RING.
Recent analysis showed that the MDMX AD engages in intramolecular interactions with the N terminus and RING (19) . The MDMX intramolecular interactions can be disrupted by mutating two conserved residues in the AD (W200S/W201G). To test whether W200/W201 are important for AD binding to the p53 core, PFR analysis was performed by using MDMXc3-W200S/W201G mutant. The AD containing SG mutation showed significantly reduced binding to p53 (Fig. 3B , compare ratio of lanes 1/2 vs. 3/4), whereas the RING domain from the SG mutant retained strong binding to p53. Therefore, the conserved W200/W201 residues are important for AD binding to p53.
CK1α disrupts the intramolecular interaction between MDMX N terminus and AD, thus stimulating the N-terminal binding to p53 (18, 19) . We found that under stringent PFR assay condition (0.5% Nonidet P-40; Fig. S3 A and B) , CK1α also stabilized the secondary MDMX AD-p53 binding (Fig. 3C , note the change in ratio of lanes 1/2 vs. 3/4). Mutation of the CK1α phosphorylation site on MDMX (MDMXc3-S289A) abrogated the stimulation by CK1α (Fig. 3C , lanes 7/8 vs. 9/10). The CK1α-D136N kinase-dead mutant also failed to stimulate AD-p53 binding (Fig. 3C , lanes 1/2 vs. 5/6). The effect of CK1α on RING-p53 binding was not determined in this experiment because of difficulty in detecting the small RING fragment. To address this issue, we repeated the analysis by using the MDMXc2 construct (without the C-terminal PreScission site) that produced a larger C-terminal SQ-RING fragment. CK1α increased AD-p53 binding without significant effect on RING-p53 binding (Fig. 3D, lanes 1/2 vs. 3/4) . The results suggest that CK1α cooperates with MDMX to inhibit p53 DNA binding by phosphorylating S289, enabling the AD to bind p53 core domain with higher affinity.
RING-p53 Interaction Contributes to p53 Inactivation. In the PFR assay, the binding of RING to p53 was as stable as the canonical N-terminal interaction (Fig. 2B) . However, the RING was not needed for inhibiting p53 DNA binding, as suggested by the RING deletion mutant (MDMX-1-430, Fig. 1B) . We tested whether the RING-p53 binding has other roles such as preventing dissociation of the MDMX-p53 complex. p53-loaded beads were used to capture MDMX deletion mutants (Fig. 4A) . The beads containing the preformed complex were incubated in buffer, and the dissociation of MDMX from the beads was monitored. The MDMX constructs containing the RING domain had no significant dissociation from p53 during the 4-h span. MDMX mutants without the RING domain (1-200, 1-300) showed significant dissociation (Fig. 4B) . The results suggest that the canonical p53-binding domain (1-100) interacts with p53 in a reversible manner. Presence of the RING domain stabilizes the MDMX-p53 complex by providing a strong secondary interaction with p53. When GST-p53-1-82 (without the core domain) was used for the binding stability analysis, all MDMX constructs showed similar degrees of dissociation, consistent with the absence of stabilizing effect from the RING (Fig. 4C) .
To test whether the RING-p53 interaction contributes to p53 inhibition, luciferase assay was used to compare the ability of MDMX mutants to inhibit p53. Against the full-length Gal4-p53-1-393, the MDMX-Δ200-304 mutant was a stronger p53 inhibitor than MDMX-1-200 and MDMX-1-300, consistent with stabilization of the MDMX-p53 complex by the RING (Fig. 4D) . When the MDMX mutants were tested for inhibition of p53 transactivation domain alone (Gal4-p53-1-52), MDMX-Δ200-304 no longer had an advantage over MDMX-1-200 and MDMX-1-300, consistent with the absence of secondary interactions (Fig. 4E) . Full-length MDMX activity was moderate in this assay despite containing the RING domain, probably due to multiple intramolecular interactions (19) . The results suggest that the RING contributes to p53 inhibition by stabilizing the MDMX-p53 complex, thus helping to conceal the p53 transactivation domain. This function may cooperate with AD inhibition of p53 DNA binding to regulate transcriptional output.
MDMX Inhibits p53 DNA Binding in Vivo. Knockdown of MDMX in tumor cell lines did not cause a significant increase in p53, but induced the expression of p53 targets (p21, PUMA, MDM2) at both protein and mRNA levels ( Fig. 5 A and B) . Knockdown of CK1α also induced p53 targets without affecting p53 level ( Fig. 5  A and B and Fig. S4 ). ChIP analysis showed that p53 binding to p21/PUMA/MDM2 promoters increased after depletion of MDMX or CK1α (Fig. 5C) . Therefore, MDMX and CK1α appeared to inhibit p53 in part by blocking its DNA binding.
MDMX has been shown to block p53 activation by stress such as ARF expression, ribosomal stress, and DNA damage. To test whether ARF overcomes MDMX inhibition of p53 DNA binding, MDMX was stably transfected into a U2OS cell line expressing (B and C) Beads loaded with GST-p53 or GST-p53-1-82 were used to capture MDMX mutants expressed in H1299 lysate. After removal of unbound MDMX by washing, the beads were incubated with excess buffer for indicated times at 4°C, and the MDMX remaining bound to the beads were analyzed by Western blot. Quantitation is shown below the blots. (D and E) Gal4-p53 and Gal4-p53-1-52 activation of Gal4-TK-luc reporter in MDMX/p53 double-null MEF cells was used to measure the inhibitory effect of different MDMX mutants. Statistically significant differences from the controls are marked by asterisk (Student's t test; *P < 0.05).
IPTG-inducible ARF (NARF6) (20) . Treatment of NARF6 cells with IPTG induced ARF, resulting in p53 accumulation and induction of p21. MDMX strongly inhibited p53 activation by ARF (Fig. S5A) . Unlike ARF, IR was able to moderately activate p53 in the presence of MDMX, but failed to overcome the inhibition by MDMX-S367A (Fig. S5B) . ChIP analysis showed that in the presence of MDMX and MDMX-S367A, the p53 stabilized by ARF and IR had significantly reduced DNA binding (Fig. S5 C  and D) . Activation of p53 DNA binding by IR requires phosphorylation of S367. The results suggest that MDMX inhibits p53 DNA binding in vivo. This function is regulated by phosphorylation of S367, which disrupts MDMX-CK1α interaction (18).
CK1α Is Required for MDMX Inhibition of p53 DNA Binding in Vivo. To further test the role of CK1α, we took advantage of the MDMX-S367A mutant that binds CK1α constitutively after IR (18) . We generated U2OS cells stably expressing MDMX and MDMX-S367A mutant. MDMX and MDMX-S367A binding to p53 were reduced after knockdown of CK1α, confirming previous reports that CK1α is involved in stimulating MDMX-p53 binding (Fig.  6A) . Next, the impact of CK1α knockdown on MDMX-S367A and MDMX-S289A/S367A activities after DNA damage was determined. MDMX-S367A strongly inhibited p21 induction by IR (Fig. 6B) . Knockdown of CK1α or mutating the CK1α phosphorylation site (S289A/S367A double mutant) partially abrogated the ability of S367A mutant to block p21 induction. The S289A/S367A double mutant did not respond further to CK1α knockdown (Fig. 6B) . ChIP and RT-PCR analyses showed that both CK1α knockdown and S289A mutation partially abrogated the ability of S367A mutant to inhibit p53 DNA binding (Fig. 6 C and D) and p21/PUMA mRNA induction (Fig. S6 A  and B) . Therefore, MDMX inhibition of p53 DNA binding in vivo requires the cooperation of CK1α and phosphorylation of S289. It is noteworthy that although MDMX-S289A/S367A did not inhibit p53 binding to the PUMA promoter (Fig. 6D) , it still partially inhibited PUMA mRNA induction by IR (Fig. 6B) , suggesting that DNA binding is a contributing factor but not the only mechanism by which MDMX inhibits p53 transcriptional output.
Discussion
Several studies showed that MDMX inhibits p53 transcriptional function without increasing its degradation. The results described above suggest a two-step model of p53 inhibition by MDMX (Fig.  6E) : The binding between MDMX and p53 is initiated by the canonical interaction between the N-terminal domains. Subsequently, the MDMX AD and RING domains also interact with the p53 core domain, causing the loss of sequence-specific DNA binding. CK1α plays a critical role in this process by stimulating the primary p53 binding by the MDMX N-terminal pocket, and promoting the secondary binding of MDMX AD to p53 core domain. In this model, the MDMX AD has opposite effects on p53, depending on whether CK1α is present. In the absence of CK1α, the AD acts as a p53 mimetic and autoinhibitory domain to reduce MDMX-p53 binding. In the presence of CK1α, the AD becomes an active participant in suppressing p53 DNA binding activity. This mechanism is subjected to tight regulation by DNA damage signaling, because Chk2-mediated phosphorylation of S367 disrupts MDMX-CK1α interaction and inhibits MDMXp53 binding (18) . Our model does not rule out other mechanisms of p53 inhibition, because MDMX mutants without the AD can inhibit p53 by blocking the transactivation domain.
Peptides and small molecule inhibitors of the MDMX N-terminal pocket efficiently inhibit MDMX-p53 binding. Therefore, MDMX-p53 complex formation strictly depends on the MDMX N-terminal p53BD. Although the separated AD and RING fragments interact with p53 poorly in vitro, the PFR assay revealed that in the mature complex, these domains bind to p53 with significant stability. It is possible that only the MDMX N-terminal domain has the conformation and rapid on/off binding rates that enable it to seek out p53 from a crowded intracellular environment. In contrast, the AD and RING domains are optimized for rapid binding to other partners such as CK1α and MDM2. Their binding to p53 may require slow conformational changes, which is only relevant after formation of the initial complex through the N terminus.
The partially unstructured MDM2 AD has significant binding affinity for ribosomal proteins, ARF, transcription repressors, and chromatin modifying enzymes. MDM2 AD also provides a second binding site to p53 and Notch, thus leading to the suggestion of a two-site binding model for these interactions (21, 22) . The MDM2 AD binds to p53 core domain with measurable affinity in pulldown and ITC assays, induces a Pab240-reactive conformational change, and inhibits p53 DNA binding in the full-length complex (14, 15) . In comparison, MDMX alone was incapable of inducing these changes, and requires CK1α cooperation to inhibit p53 DNA binding. The MDM2 AD-p53 core interaction is mainly charge-mediated (14) . The MDMX AD region has lower density of negative charges compared with MDM2, thus it may require phosphorylation on S289 by CK1α, which increases negative charges and binding affinity to p53. The MDM2 AD has been shown to bind to the DNA-binding surface of p53 core domain as a nucleic acid mimic (14) . It is possible that the MDMX AD acts in a similar fashion after phosphorylation by CK1α.
In addition to the AD-core interaction, the PFR assay also identified stable binding between the RING and p53 core domain. This interaction is important for stabilizing the full-length MDMX-p53 complex. The significance of the MDMX RING was demonstrated by mutant mouse models with point mutation or internal deletion in the RING (23, 24) . The RING internal deletion results in p53 activation and embryonic lethality without increase of p53 level (23) . Although the study was interpreted mainly from the perspective of MDM2-MDMX heterodimer formation, our results suggest that the phenotypes may also partly result from the disruption of RING-p53 interaction. In fact, the MDMX RING internal deletion mutant showed reduced p53 binding, which is consistent with our results (23) .
It remains to be determined whether the secondary interactions described here are merely byproducts of the specific N-terminal binding, or represent optimized interactions evolved for important functions. It is conceivable that following binding by the N termini, other domains of p53 and MDMX are forced to interact. Some of the lowest energy configurations may involve forming new domain interactions. Because such structural rearrangements will have functional consequences, they will be finetuned by mutations and natural selection. The unique characteristics of secondary interactions may make them difficult to detect by using conventional binding assays. The PFR assay allows the discovery of interactions that preexist in full-length protein complexes, providing clues for further investigation. We speculate that secondary interactions may occur frequently in multidomain protein complexes and play important roles in mediating signaling.
Materials and Methods
Plasmids and Cell Lines. The MDMXc3 sequence contains LEVLFQGPDYKDDDDK, LEVLFQGPEEQKLISEEDL, and LEVLFQGPYPYDVPDYA inserted after MDMX residues 140, 350, and 429 respectively. Cell lines H1299 (p53-null), A549, JEG3, MCF7 and U2OS (p53 wild type), MDMX/p53 double null MEF cells (41.4), NARF6 (U2OS with inducible ARF), and U2OS stably infected with MDMX lentiviruses were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% (vol/vol) FBS. GST-PreScission protease fusion was purified from Escherichia coli by using glutathione agarose column. This study did not involve human subjects. Therefore no Institutional Review Board approval was necessary.
Proteolytic Fragment Release Assay. H1299 cells were transiently transfected with MDMXc3 plasmid by using standard calcium phosphate precipitation protocol. Cells were lysed by using IP buffer [150 mM NaCl, 50 mM Tris·HCl pH 8.0, 0.5% Nonidet P-40, 0.5 mM DTT, 10% (vol/vol) glycerol]. Cell lysate (1 mL) from ∼2 × 10 6 cells (a 10-cm plate) was incubated with 20 μL of packed glutathione agarose beads loaded with ∼5 μg of GST-p53 for 2 h at 4°C. The beads were washed two times with PreScission buffer (150 mM NaCl, 10 mM Hepes pH 7.5, 0.05% Nonidet P-40, 0.5 mM DTT, 10% glycerol) and suspended in 100 μL of PreScission buffer. PreScission protease was added to 0.2 μg/μL final concentration, and the beads were incubated at 23°C with shaking for 20-60 min. The protease digestion mixture was centrifuged for 10 s, and the beads (bound material) and supernatant (released material) were separated. The beads were washed once with PreScission buffer to remove residual supernatant. The beads and supernatant were boiled in Laemmli sample buffer, and analyzed by SDS/PAGE and Western blot by using 8C6, FLAG, Myc, or HA antibodies to determine the bound/released ratio of each fragment. Additional experimental procedures are described in SI Materials and Methods.
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